疑似合并慢性肾脏病的冠状动脉疾病患者心脏磁共振的临床影响(AQUAMARINE-CKD研究):随机对照试验研究方案
AQUAMARINE-CKD是一项开放、平行组、前瞻性、多中心随机对照试验,计划纳入524例根据日本城市人群危险因素分类(Suita评分)评估为冠状动脉疾病高风险的慢性肾脏病患者,从6家机构招募。参与者按1:1随机接受包含非对比T1加权成像和冠状动脉磁共振血管成像的心脏磁共振检查(心脏磁共振组)或包含负荷心肌闪烁显像的标准检查(对照组)。主要结局为研究检查后1年时心血管事件的复合终点:全因死亡、冠状动脉疾病死亡、非致死性心肌梗死、非致死性缺血性卒中及缺血驱动的非计划冠状动脉干预(经皮冠状动脉介入治疗或冠状动脉旁路移植术)。
要点
- 心脏磁共振无需对比剂且不受冠状动脉钙化影响,或可用于慢性肾脏病患者的冠状动脉疾病风险评估。
- 研究计划纳入524例慢性肾脏病且冠状动脉疾病高风险患者,按1:1随机分入心脏磁共振组或标准检查组。
- 主要结局为研究检查后1年时心血管事件复合终点,包括全因死亡、冠状动脉疾病死亡、非致死性心肌梗死、非致死性缺血性卒中及缺血驱动的非计划冠状动脉干预。
核心结论
- 若T1加权成像联合冠状动脉磁共振血管成像有助于慢性肾脏病患者的冠状动脉疾病风险评估,本研究将对高风险慢性肾脏病患者的管理具有重要临床意义。
研究设计与样本
- AQUAMARINE-CKD是一项开放、平行组、前瞻性、多中心随机对照试验,计划纳入524例慢性肾脏病患者,从6家机构招募。
- 纳入标准为根据日本城市人群危险因素分类(Suita评分)评估为冠状动脉疾病高风险。
- 参与者按1:1随机分入心脏磁共振组(接受包含非对比T1加权成像和冠状动脉磁共振血管成像的检查)或对照组(接受包含负荷心肌闪烁显像的标准检查),随机化通过基于网络的系统进行。
关键数值与推荐
- 主要结局为研究检查后1年时心血管事件的复合终点:全因死亡、冠状动脉疾病死亡、非致死性心肌梗死、非致死性缺血性卒中及缺血驱动的非计划冠状动脉干预(经皮冠状动脉介入治疗或冠状动脉旁路移植术)。
- 试验注册号为日本临床试验注册中心(jRCT)1,052,210,075,注册日期为2021年9月10日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although screening for coronary artery disease (CAD) using computed tomography coronary angiography in patients with stable chest pain has been reported to be beneficial, patients with chronic kidney disease (CKD) might have limited benefit due to complications of contrast agent nephropathy and decreased diagnostic accuracy as a result of coronary artery calcifications. Cardiac magnetic resonance (CMR) has emerged as a novel imaging modality for detecting coronary stenosis and high-risk coronary plaques without contrast media that is not affected by coronary artery calcification. However, the clinical use of this technology has not been robustly evaluated. METHODS: AQUAMARINE-CKD is an open parallel-group prospective multicenter randomized controlled trial of 524 patients with CKD at high risk for CAD estimated based on risk factor categories for a Japanese urban population (Suita score) recruited from 6 institutions. Participants will be randomized 1:1 to receive a CMR examination that includes non-contrast T1-weighted imaging and coronary magnetic angiography (CMR group) or standard examinations that include stress myocardial scintigraphy (control group). Randomization will be conducted using a web-based system. The primary outcome is a composite of cardiovascular events at 1 year after study examinations: all-cause death, death from CAD, nonfatal myocardial infarction, nonfatal ischemic stroke, and ischemia-driven unplanned coronary intervention (percutaneous coronary intervention or coronary bypass surgery). DISCUSSION: If the combination of T1-weighted imaging and coronary magnetic angiography contributes to the risk assessment of CAD in patients with CKD, this study will have major clinical implications for the management of patients with CKD at high risk for CAD. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) 1,052,210,075. Registered on September 10, 2021.
引用
- Noguchi T, Ota H, Matsumoto N, et al. Clinical impact of cardiac magnetic resonance in patients with suspected coronary artery disease associated with chronic kidney disease (AQUAMARINE-CKD study): study protocol for a randomized controlled trial. Trials. 2022. PMID: 36280852. doi:10.1186/s13063-022-06820-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。